Whenever intestinal metaplasia was present in the mucosa, 5 ,um sections were cut and stained with Alcian blue pH 2.5/periodic acid Schiff (AB pH 2-5/PAS) and high-irondiamine/Alcian blue for subtyping of intestinal
carcinoma was studied in relation to the histological type (Lauren classification) and the type of growth pattern, including the chronology of p53 protein accumulation during carcinogenesis. Forty five, paraffin embedded gastrectomy specimens from early carcinomas were examined for the presence of chronic atrophic gastritis, subtypes of intestinal metaplasia, and dysplasia. The Lauren type and the type of growth pattern were reassessed for all early carcinomas. p53 Protein accumulation was examined using the monoclonal antibody Complete absence of p53 protein accumulation was observed in normal gastric mucosa, chronic atrophic gastritis, and intestinal metaplasia, irrespective of subtype. In gastric dysplasia (one mild, two moderate, and one severe), only severe dysplasia was p53 positive. Intestinal 
Methods

TISSUES
Forty five gastrectomy specimens from patients with early gastric cancer were retrieved from the files. The tissues had been fixed in 10% formalin and processed to paraffin wax by routine methods. Chronic atrophic gastritis was diagnosed using the criteria of the Sydney classification. '9 20 Whenever intestinal metaplasia was present in the mucosa, 5 ,um sections were cut and stained with Alcian blue pH 2.5/periodic acid Schiff (AB pH 2-5/PAS) and high-irondiamine/Alcian blue for subtyping of intestinal metaplasia according to Filipe.21 were reassessed using the original paraffin embedded, haematoxylin and eosin stained sections. In rare cases of disagreement, consensus was reached after discussion.
IMMUNOHISTOCHEMISTRY
To assess p53 protein accumulation, the commercially available monoclonal antibody DO-7 (DAKO, Glostrup, Denmark) was used in combination with the avidin-biotin-peroxidase method, as described by Hsu et al.24 , which can be used on (archival) paraffin embedded material, is a mouse monoclonal antibody raised against recombinant human wild type p53 protein expressed in Escherichia coli and recognises both wild type and mutant type p53 protein. The exact binding site of DO-7 is unknown, but is probably between amino acids [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] in the N-terminus of the p53 protein (DAKO data sheet).
Briefly, 4 ,u sections were cut and dewaxed in xylene. After rehydration through alcohol, the sections were immersed in 03%/o hydrogen peroxidase in methanol for 30 minutes to block endogenous peroxidase activity. After washing with phosphate buffered saline (PBS), sections were treated with 10% normal goat serum to reduce non-specific antibody binding. All steps were carried out at room temperature. To improve p53 immunoreactivity, sections were treated with an antigen retrieval solution (10 mM citric acid monohydrate pH 6.0), heated in a microwave. After washing with PBS, DO-7 was applied for one hour. After further washing with PBS, sections were incubated with a biotinylated rabbit antimouse second-stage antibody (DAKO). After further washing with PBS, peroxidase-conjugated streptavidin was applied. Peroxidase activity was demonstrated by adding diaminobenzidine as a chromogen. The sections were counterstained with haematoxylin. Negative control sections were processed without the primary antibody. Positive control sections were processed from a breast adenocarcinoma, previously shown to express high levels of p53 protein.
The proportion of tumour cells with nuclear p53 protein accumulation was arbitrarily divided into five groups: 0%, <10%, 10-30%, 30-60%, and :60% of the total tumour cell population per section. Four sections from each tumour were scored. A tumour was scored as p53 positive when at least 10% of the tumour cells showed nuclear p53 protein accumulation. In p53 positive tumours, the intensity of nuclear p53 immunostaining was graded as (1) weak but definitely visible and (2) strong and clearly visible. Ultimately, for each p53 positive early gastric cancer, a product score of % p53 positive cellsxstaining intensity was calculated as follows:
High grade dysplasia with most cells showing strong nuclear p53 immunostaining (original magnification X 10).
10-30%=/1, 30-60%=2, -60%=3, weak=1 and strong=2.
In cases of normal gastric mucosa, chronic active gastritis, intestinal metaplasia subtypes, and dysplasia, the same scoring criteria which was used in cases of early gastric cancer, were applied. Scoring was performed independently by two of the authors (MC/PB). In rare cases of disagreement, consensus was reached after discussion.
STATISTICS
The x2 test was used for statistical analysis, unless stated otherwise. A p value <0 05 was considered significant.
Results
HISTOLOGY
Normal gastric mucosa was observed in all gastrectomy specimens. Chronic both, for example, may lead to biased conclusions. We used monoclonal antibody DO-7, whereas other investigators used either polyclonal antibody CM-133 34 or monoclonal antibody Pab 1801.35 All three antibodies recognise both wild type and mutant type p53 protein, despite differences in the epitopes recognised.40-42 DO-7, however, has been reported to be superior to both CM-1 or Pab 1801 on formalin fixed, paraffin embedded tissues in detecting missense p53 gene mutations, especially when combined with target unmasking fluid.43 Our data therefore suggest that missense p53 gene mutation is a late event in gastric carcinogenesis. In contrast, the only study to date which has used p53 gene mutational analysis (single strand conformation polymorphism with direct DNA sequencing) as an adjunct to immunohistochemistry has suggested that p53 gene mutation is an early pathogenic event in gastric carcinogenesis. Missense mutations, however, were found only from dysplasia onwards. Moreover, the mutations found in three of eight cases of intestinal metaplasia did not change the amino acid sequence of the p53 protein, thereby leaving the p53 protein in its wild type form. Finally, it was not stated whether or not the intron 5 mutation in intestinal metaplasia affected the splice site acceptor region. Its conclusion, therefore, that p53 gene mutation is an early instead of a late pathogenic event in gastric carcinogenesis seems unlikely.44 Apparently, p53 is not involved in the (early) progression from metaplastic to dysplastic epithelium, but is involved in the malignant transformation from dysplasia onwards.
According to our criteria, 60% of early gastric cancers were p53 positive, and similar percentages have been reported in both early and advanced carcinomas.16 33 No significant difference was found in the proportion of p53 positive tumours between intestinal and diffuse type early gastric cancers. This finding does not necessarily preclude the possibility of a different pathogenesis of both tumour types but could merely reflect the occurrence of missense p53 gene mutations during a final common pathway of genetic alterations.
Whether or not both tumour types differ in the occurrence of nonsense p53 gene mutations remains unanswered in our study. Immunohistochemistry can not generally detect these mutations since they lead to stop codon formation and premature termination of translation. Interestingly, significant differences in immunostaining characteristics were observed between both types of early gastric cancer, best exemplified by the median product score of the % p53 positive cellsXstaining intensity. Of course, it is tempting to speculate that intestinal and diffuse type early gastric cancers differ in their p53 mutational spectrum or in the expression of viral or cellular proteins that interact with p53. Furthermore, differences in the expression levels of the p53 gene in both tumour types, in cell cycle kinetics, and finally in the p53 protein degradation pathway might be considered. However, one should also cautiously include the possibility that microwave pretreatment has influenced results, since this technique may lower the immunohistochemical detection threshold of the p53 protein45 and may influence immunostaining results appreciably, as has been shown by Lambkin et al. 46 As a result, it cannot entirely be ruled out that in some cases, especially in those with weak nuclear staining intensity, stabilised inactivated wild type p53 protein is being detected instead of mutant forms. Ideally, therefore, one should combine microwave pretreatment with the use of an antibody that specifically recognises mutant forms, as has been reported for Pab 240,47 but unfortunately this antibody can not be applied to formalin fixed, paraffin embedded tissues. 42 43 It has been reported that p53 protein accumulation in gastric carcinoma is correlated with a higher propensity for lymph node metastasis and with an unfavourable clinical outcome independent of tumour stage, as measured by early relapse and death.1618
Moreover, recent findings on the role of p53 in the apoptotic response of cells to genotoxic stimuli such as radiation and anticancer agents48-50 lend further support to the concept that p53 positive tumours may constitute a distinct group of gastric carcinomas with a higher malignant potential than p53 negative gastric carcinomas. Since, in cases of early gastric cancer, the type of growth pattern may also strongly influence malignant potential and clinical outcome, we examined whether growth patterns and p53 protein accumulation are correlated. Whereas the pen A type, in contrast to the other growth types, has been reported to have a high propensity for blood vessel invasion and lymph node metastasis and to have the worst prognosis after surgery due to early postoperative hepatic metastasis,14 we found no significant difference in p53 protein accumulation between the various growth types.
In conclusion, p53 protein accumulationusually reflecting missense p53 gene mutation -should be considered as a late event in gastric carcinogenesis. Moreover, we suggest that missense p53 gene mutation occurs in a final pathway of genetic alterations common to both intestinal and diffuse type early gastric cancer. Finally, it seems that mechanisms other than p53 protein accumulation underlie the reported differences in biological behaviour of early gastric carcinomas with different types of growth pattern. 
